Search research articles
Contact Us
Filters
Showing results (251-260 of 262) with videos related to
Page
of 27
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
June 28, 2020
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study
Shun Lu, Gongyan Chen, Yuping Sun, et al.
Eclinicalmedicine
|
November 29, 2021
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
Rui Wan, Xiaorong Dong, Qun Chen, et al.
Cancer Biology & Medicine
|
May 24, 2019
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology
Xuchao Zhang, Zhiyong Liang, Shengyue Wang, et al.
Hepatology International
|
November 21, 2024
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
George Lau, Shuntaro Obi, Jian Zhou, et al.
Liver Cancer
|
August 11, 2022
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Yongkun Sun, Wen Zhang, Xinyu Bi, et al.
Cancer Cell
|
March 4, 2022
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Zi-Xian Wang, Chengxu Cui, Jun Yao, et al.
Cancer Communications (London, England)
|
June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial
Yuankai Shi, Kaijian Lei, Yuming Jia, et al.
Nature Medicine
|
March 27, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Lin Shen, Yanqiao Zhang, Ziyu Li, et al.
Nature Medicine
|
January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Lin Shen, Yanqiao Zhang, Ziyu Li, et al.
Journal of Hematology & Oncology
|
February 16, 2019
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)
Jian Li, Ying Yuan, Fan Yang, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 262) with videos related to
Sort By:
Page
of 27
Lung Cancer (Amsterdam, Netherlands)
|
June 28, 2020
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study
Shun Lu, Gongyan Chen, Yuping Sun, et al.
Eclinicalmedicine
|
November 29, 2021
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
Rui Wan, Xiaorong Dong, Qun Chen, et al.
Cancer Biology & Medicine
|
May 24, 2019
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology
Xuchao Zhang, Zhiyong Liang, Shengyue Wang, et al.
Hepatology International
|
November 21, 2024
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
George Lau, Shuntaro Obi, Jian Zhou, et al.
Liver Cancer
|
August 11, 2022
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Yongkun Sun, Wen Zhang, Xinyu Bi, et al.
Cancer Cell
|
March 4, 2022
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Zi-Xian Wang, Chengxu Cui, Jun Yao, et al.
Cancer Communications (London, England)
|
June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial
Yuankai Shi, Kaijian Lei, Yuming Jia, et al.
Nature Medicine
|
March 27, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Lin Shen, Yanqiao Zhang, Ziyu Li, et al.
Nature Medicine
|
January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Lin Shen, Yanqiao Zhang, Ziyu Li, et al.
Journal of Hematology & Oncology
|
February 16, 2019
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)
Jian Li, Ying Yuan, Fan Yang, et al.
Page
of 27